Tarsons Products · forward-looking guidance across the available source record.
Guidance tracker
With new capacity expansion, steady demand for existing products, and gradual scale-up in new product categories (cell culture, bioprocess), management projects accelerated revenue growth trajectory moving forward.
Partial capitalization of ParSCH facility has accelerated depreciation; full facility commissioning expected with revenue contribution scaling over 3-4 years as customer qualification progresses.
Sampling will begin immediately upon commissioning (within weeks across India), but scale-up to optimal capacity levels expected over 3-4 years through progressive customer SOP approvals.
Current PAT decline is attributable to higher depreciation (₹6.66 crore vs ₹3.65 crore in 9M) from partial capitalization; margins expected to return to normalized levels once facility is fully commissioned and revenue scales.